Gemin X: Clinical Trials

8 completed, 2 terminated. 10 Phase 2, 4 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	10	Completed 8, Terminated 2
Phase 1	4	Completed 3, Terminated 1

Follow Gemin X: new trials by email

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Obatoclax for Systemic Mastocytosis Obatoclax Mesylate - Leukemia, Systemic Mastocytosis	Phase 2	Terminated	M.D. Anderson Cancer Center	3	2009-06-01	2011-11-04
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma Obatoclax Mesylate, Temozolomide - Metastatic Melanoma	Phase 1 / Phase 2	Terminated	Gemin X	1	2008-06-01	2016-07-22
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) Obatoclax, Carboplatin/etoposide - Extensive-stage Small Cell Lung Cancer	Phase 1 / Phase 2	Completed	Gemin X	218	2008-05-01	2016-07-21
Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) Obatoclax - AML	Phase 2	Completed	Gemin X	18	2008-04-01	2013-08-26
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL) Obatoclax mesylate, Rituximab - Lymphoma, Follicular	Phase 2	Completed	Gemin X	7	2007-03-01	2016-07-22
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS) Obatoclax mesylate (GX15-070MS) - Myelodysplastic Syndromes	Phase 2	Completed	Gemin X	24	2006-12-01	2013-08-26
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer Obatoclax mesylate 250 ml, Docetaxel - Lung Cancer	Phase 1 / Phase 2	Completed	Gemin X	47	2006-10-01	2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) Obatoclax mesylate, Bortezomib - Mantle-Cell Lymphoma	Phase 1 / Phase 2	Completed	Gemin X	24	2006-10-01	2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia Obatoclax mesylate (GX15-070MS) - Myelofibrosis	Phase 2	Completed	Gemin X	22	2006-07-01	2013-08-26
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma Obatoclax mesylate (GX15-070MS) - Hodgkin's Lymphoma	Phase 2	Completed	Gemin X	13	2006-07-01	2012-08-06

Conditions studied

Hodgkin Disease (1)  ·  Leukemia (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lung Neoplasms (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Mastocytosis, Systemic (1)  ·  Melanoma (1)  ·  Myelodysplastic Syndromes (1)  ·  Primary Myelofibrosis (1)  ·  Small Cell Lung Carcinoma (1)

Interventions

obatoclax (10)  ·  1-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxycarbonyloxymethyl)-4-(N'-cyano-N''-(6-(4-chlorophenoxy)hexyl)-N-guanidino)pyridinium (1)  ·  Bortezomib (1)  ·  Docetaxel (1)  ·  EC regimen (1)  ·  Rituximab (1)  ·  Temozolomide (1)

Countries

United States (10)  ·  Canada (4)  ·  Bulgaria (1)  ·  Czechia (1)  ·  Hungary (1)  ·  India (1)  ·  Poland (1)  ·  Romania (1)  ·  Serbia (1)  ·  United Kingdom (1)

Top investigators

Jean Viallet, MD (7)  ·  Mark Berger, MD (2)  ·  Srdan Verstovsek, MD (1)

Results publications

PMID 20709666, PMID 22383790, PMID 24997137, PMID 25052051, PMID 25285531